Pancreatic Cancer Research

ResearcherKyoto UniversityActive in the last 2 years

Kazuto Nishio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8275-0846; OpenAlex author ID A5004282323, A5112565205. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 9

  1. ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and Pancreatic Cancer Cells. Co-author DOI 10.1155/2024/7683793↗
  2. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. Co-author DOI 10.1007/s10147-023-02396-w↗
  3. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca… Co-author DOI 10.3390/cells11040702↗
  4. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001672↗
  5. Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. Last author DOI 10.3892/ijo.2017.3961↗
  6. Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Last author DOI 10.1016/j.canlet.2014.10.037↗
  7. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  8. Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Last author DOI 10.1186/1476-4598-13-126↗
  9. Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. Last author DOI 10.1093/jjco/hyr178↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Golam Iftakhar Khandakar · 2 shared papers, 2022–2024 · strength 0.37
  2. Teruaki Takasaki · 2 shared papers, 2022–2024 · strength 0.37
  3. Reiko Sugiura · 2 shared papers, 2022–2024 · strength 0.37
  4. Masatoshi Kudo · 5 shared papers, 2012–2023 · strength 0.33
  5. Ken Kamata · 2 shared papers, 2017–2023 · strength 0.22
  6. Hitoshi Okada · 1 shared paper, 2024 · strength 0.21
  7. Yosuke Togashi · 4 shared papers, 2014–2017 · strength 0.18
  8. Masayuki Kitano · 4 shared papers, 2012–2017 · strength 0.17
  9. Kosuke Minaga · 1 shared paper, 2023 · strength 0.16
  10. Yasuo Otsuka · 1 shared paper, 2023 · strength 0.16
  11. Mamoru Takenaka · 1 shared paper, 2023 · strength 0.16
  12. Hidekazu Tanaka · 1 shared paper, 2023 · strength 0.16
  13. Kentaro Yamao · 1 shared paper, 2023 · strength 0.16
  14. Tomohiro Kondo · 1 shared paper, 2020 · strength 0.10
  15. Manabu Muto · 1 shared paper, 2020 · strength 0.10
  16. Masashi Kanai · 1 shared paper, 2020 · strength 0.10
  17. Junichi Matsubara · 1 shared paper, 2020 · strength 0.10
  18. Hiroki Sakamoto · 2 shared papers, 2014–2015 · strength 0.08
  19. Eri Banno · 1 shared paper, 2017 · strength 0.06
  20. Akira Fukutomi · 1 shared paper, 2015 · strength 0.04
  21. Shinichi Ohkawa · 1 shared paper, 2015 · strength 0.04
  22. Nobumasa Mizuno · 1 shared paper, 2015 · strength 0.04
  23. Masayuki Furukawa · 1 shared paper, 2015 · strength 0.04
  24. Narikazu Boku · 1 shared paper, 2015 · strength 0.04
  25. Hiroshi Ishii · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.